Dr. Donna Morgan Murray appointed as Nativis Chief Regulatory Officer

Dr. Donna Morgan Murray has been appointed as Nativis Chief Regulatory Officer with immediate effective.

Murray is author of more than 60 publications in peer-referenced journals, and has served on the board of non-profits and other organizations. Most recently the Head of Global Quality & Regulatory Compliance at Bristol-Myers Squibb, Murray has held that role since 2014. Prior to that, she was the President of ZymoGenetics Inc.,. Over the past 20 years, Murray has led and directed regulatory strategy and operations for Bristol-Myers Squibb, CuraGen Corporation, and Procter & Gamble Pharmaceuticals. Murray began her professional career in 1984 as a staff scientist in the Anti-Infective Research Department with Norwich Eaton Pharmaceuticals, Inc., a Procter & Gamble Company.

Murray holds a PhD in Immunology from The University of Texas Health Science Center at Houston, where she conducted research in infectious disease & clinical microbiology. Outside of her professional work, she serves as an officer and member of the board of K9 Crime Stoppers Inc. and was the Chief Operating Officer for Independence Guide Dogs.

Nativis CEO, Chris Rivera said that they are very excited to welcome Dr. Donna Morgan Murray as Chief Regulatory Officer to Nativis. Dr. Murray’s extensive professional accomplishments and medical background will provide Nativis with a broad range of experience in worldwide regulatory policy, feasibility and strategy. As they develop their technology for the treatment of cancer and other serious diseases, it is critical to consider the regulatory pathway for the Voyager system and develop a comprehensive strategy that will bring us towards regulatory approval.

Murray said that she is very pleased to join Nativis as the Chief Regulatory Officer and look forward to applying my experience in the biopharmaceutical industry toward developing a strong regulatory strategy for the Company’s ulRFE technology. Shelook forward to working to ensure that Nativis is well prepared to meet regulatory requirements and milestones for its unique technology platform and to streamline the regulatory process and help rapidly move forward with the Voyager system.